BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 27727448)

  • 1. Impaired calcium mobilization in natural killer cells from chronic fatigue syndrome/myalgic encephalomyelitis patients is associated with transient receptor potential melastatin 3 ion channels.
    Nguyen T; Johnston S; Clarke L; Smith P; Staines D; Marshall-Gradisnik S
    Clin Exp Immunol; 2017 Feb; 187(2):284-293. PubMed ID: 27727448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel identification and characterisation of Transient receptor potential melastatin 3 ion channels on Natural Killer cells and B lymphocytes: effects on cell signalling in Chronic fatigue syndrome/Myalgic encephalomyelitis patients.
    Nguyen T; Staines D; Nilius B; Smith P; Marshall-Gradisnik S
    Biol Res; 2016 May; 49(1):27. PubMed ID: 27245705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of Transient Receptor Potential Melastatin 3 ion channel function in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients.
    Cabanas H; Muraki K; Eaton N; Balinas C; Staines D; Marshall-Gradisnik S
    Mol Med; 2018 Aug; 24(1):44. PubMed ID: 30134818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56 dim CD16+ and CD56 bright CD16 dim/- natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients.
    Huth TK; Staines D; Marshall-Gradisnik S
    J Transl Med; 2016 Apr; 14():97. PubMed ID: 27098723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transient receptor potential melastatin 2 channels are overexpressed in myalgic encephalomyelitis/chronic fatigue syndrome patients.
    Balinas C; Cabanas H; Staines D; Marshall-Gradisnik S
    J Transl Med; 2019 Dec; 17(1):401. PubMed ID: 31796045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis patients.
    Cabanas H; Muraki K; Balinas C; Eaton-Fitch N; Staines D; Marshall-Gradisnik S
    Mol Med; 2019 Apr; 25(1):14. PubMed ID: 31014226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of IL-2 stimulation and treatment of TRPM3 on channel co-localisation with PIP
    Eaton-Fitch N; Cabanas H; du Preez S; Staines D; Marshall-Gradisnik S
    J Transl Med; 2021 Jul; 19(1):306. PubMed ID: 34266470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired TRPM3-dependent calcium influx and restoration using Naltrexone in natural killer cells of myalgic encephalomyelitis/chronic fatigue syndrome patients.
    Eaton-Fitch N; Du Preez S; Cabanas H; Muraki K; Staines D; Marshall-Gradisnik S
    J Transl Med; 2022 Feb; 20(1):94. PubMed ID: 35172836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment.
    Cabanas H; Muraki K; Eaton-Fitch N; Staines DR; Marshall-Gradisnik S
    Front Immunol; 2021; 12():687806. PubMed ID: 34326841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naltrexone Restores Impaired Transient Receptor Potential Melastatin 3 Ion Channel Function in Natural Killer Cells From Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients.
    Cabanas H; Muraki K; Staines D; Marshall-Gradisnik S
    Front Immunol; 2019; 10():2545. PubMed ID: 31736966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transient receptor potential melastatin 3 dysfunction in post COVID-19 condition and myalgic encephalomyelitis/chronic fatigue syndrome patients.
    Sasso EM; Muraki K; Eaton-Fitch N; Smith P; Lesslar OL; Deed G; Marshall-Gradisnik S
    Mol Med; 2022 Aug; 28(1):98. PubMed ID: 35986236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation into the restoration of TRPM3 ion channel activity in post-COVID-19 condition: a potential pharmacotherapeutic target.
    Sasso EM; Muraki K; Eaton-Fitch N; Smith P; Jeremijenko A; Griffin P; Marshall-Gradisnik S
    Front Immunol; 2024; 15():1264702. PubMed ID: 38765011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot Study of Natural Killer Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis.
    Huth TK; Brenu EW; Ramos S; Nguyen T; Broadley S; Staines D; Marshall-Gradisnik S
    Scand J Immunol; 2016 Jan; 83(1):44-51. PubMed ID: 26381393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterisation of cell functions and receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME).
    Hardcastle SL; Brenu EW; Johnston S; Nguyen T; Huth T; Wong N; Ramos S; Staines D; Marshall-Gradisnik S
    BMC Immunol; 2015 Jun; 16():35. PubMed ID: 26032326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered TRPM7-Dependent Calcium Influx in Natural Killer Cells of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients.
    Du Preez S; Eaton-Fitch N; Smith PK; Marshall-Gradisnik S
    Biomolecules; 2023 Jun; 13(7):. PubMed ID: 37509075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal analysis of immune abnormalities in varying severities of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients.
    Hardcastle SL; Brenu EW; Johnston S; Nguyen T; Huth T; Ramos S; Staines D; Marshall-Gradisnik S
    J Transl Med; 2015 Sep; 13():299. PubMed ID: 26370228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of IL-2 Stimulation and TRPM7 Pharmacomodulation in NK Cell Cytotoxicity and Channel Co-Localization with PIP
    Du Preez S; Eaton-Fitch N; Cabanas H; Staines D; Marshall-Gradisnik S
    Int J Environ Res Public Health; 2021 Nov; 18(22):. PubMed ID: 34831634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and characterisation of transient receptor potential melastatin 2 and CD38 channels on natural killer cells using the novel application of flow cytometry.
    Balinas C; Cabanas H; Staines D; Marshall-Gradisnik S
    BMC Immunol; 2019 May; 20(1):14. PubMed ID: 31077146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation.
    Eaton N; Cabanas H; Balinas C; Klein A; Staines D; Marshall-Gradisnik S
    BMC Pharmacol Toxicol; 2018 Mar; 19(1):12. PubMed ID: 29587879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased frequency of ILT2-expressing CD56(dim)CD16(+) NK cells correlates with disease severity of pulmonary tuberculosis.
    Wang X; Meng X; Zheng Y; Jiang J; Yang B; Liu Y; Zhai F; Cheng X
    Tuberculosis (Edinb); 2014 Sep; 94(5):469-74. PubMed ID: 24909369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.